---
layout: default
title: Reslizumab
parent: Model Prediction Only (L5)
nav_order: 674
evidence_level: L5
indication_count: 2
---

# Reslizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Reslizumab: From Eosinophil-Mediated Disease to Immune Thrombocytopenia

## One-Sentence Summary

Reslizumab is an anti-IL-5 monoclonal antibody whose original approved indication is not recorded in this evidence pack (no Health Canada license on file). The TxGNN model predicts it may be effective for **Immune Thrombocytopenia** (thrombocytopenia due to immune destruction), but currently **0 clinical trials** and **0 publications** directly support this specific pairing — the signal rests solely on graph-based prediction (Evidence Level L5).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (no Health Canada license record in this pack; drug not marketed) |
| Predicted New Indication | Immune Thrombocytopenia (thrombocytopenia due to immune destruction) |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L5 |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data (DrugBank MOA field) is not available for reslizumab in this evidence pack. Based on the drug-level rationale that was captured, reslizumab is an anti-IL-5 monoclonal antibody whose pharmacological target is the eosinophil differentiation/survival pathway.

For the top-ranked prediction, **Immune Thrombocytopenia (ITP)**, the pack's own mechanistic assessment is skeptical: ITP is primarily driven by autoantibody-tagged platelets being cleared via Fc-receptor-mediated phagocytosis, a pathway with no established direct link to the IL-5/eosinophil axis. The high TxGNN score (99.53%) reflects knowledge-graph similarity only, without corroborating mechanistic or clinical evidence.

A second, lower-ranked candidate in this pack — **primary release disorder of platelets** (score 99.25%, Evidence Level L4) — has a somewhat stronger rationale: it is linked to platelet abnormalities seen in hypereosinophilic syndrome (HES), and one review (PMID 20565230) discusses IL-5-pathway-targeted mepolizumab in HES management. This is indirect, drug-class-level evidence (not reslizumab-specific, not disease-specific to this exact prediction), but it is more mechanistically coherent than the top-ranked ITP hypothesis and may warrant separate research follow-up.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

No Health Canada market authorization (DIN) records found for reslizumab; the product is not currently marketed in Canada per this evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Immune Thrombocytopenia) has no supporting clinical trials or literature and a mechanistically tenuous link to the drug's known IL-5/eosinophil target — this is a model-only (L5) signal. The drug is also not currently marketed in Canada, and safety data needed for an initial screen are unavailable.

**To proceed, the following is needed:**
- TFDA/regulatory label warnings and contraindications (currently a blocking data gap — required before any S1 safety screening)
- Confirmed DrugBank mechanism of action data for reslizumab
- Direct preclinical or clinical evidence connecting the IL-5/eosinophil pathway to immune-mediated platelet destruction
- Consider prioritizing **primary release disorder of platelets** (L4, HES-linked) as the more evidence-backed research question over the top-ranked ITP hypothesis
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

